BSP Pharmaceuticals is a CDMO, technologically developed to meet needs of groundbreakers and specialized in manufacturing Oncology and Immunotherapy drug, including autoimmune disease, immunotherapy & CNS among others, with a strategic interest in specifcic therapeutic areas. The facility is designed to handle conventional small molecules, Biologics and ADCs (from Conjugation to Fill Finish) and very much focused on innovative compounds. With full containment facility, applying the most advanced and safe technologies, BSP can offer a wide range of services for Pre-Clinical, Clinical and Commercial supply in compliance with the highest Quality requirements. Ensuring supply security for these life-saving product categories is the basis of the strategic partnerships that BSP has established to date.

BSP has had the foresight to anticipate the current need being ready with significant capacity to satisfy the market needs. We have a clear vision on how the company will continue its organic growth in the next 5 years and we are confirming the strategic positioning of our services in selected therapeutic areas. In alignment with our continued investment strategy, we have added substantial fill-and-finish liquid and lyophilization capacities to meet the rising demand for injectable products. We also decided to expand new capacity in novel modalities to sustain the actual demand of manufacturing of new ADCs, as well as non-conventional formulations, like lipid based nano medicines, peptides or polypeptides, proteins and oligonucleotides both in the oncology, immune-oncology and immunotherapy field.